Ventricular arrhythmia accompanied several diseases and syndromes: modern approaches to the treatment and improvement of forecast for life

Cover Page

Cite item

Full Text

Abstract

The article discusses the current problems of diagnostics, treatment, primary and secondary prevention of death in patients with genetically caused ventricular arrhythmia (VA) associated with a high risk of sudden cardiac death (SCD). We showed the results of basic clinical recommendations and studies concerning the possibility of different antiarrhythmic drugs and implantable cardioverter defibrillators (ICD) in the treatment of VA associated with arrhythmogenic right ventricular cardiomyopathy, short QT syndrome, the Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia and non-compacted myocardial layer. It was shown, that ICD application, in most cases, was the main method of secondary prevention of SCD in this group of patients. In addition, we indicated the number of issues concerning the management of VA patients with several diseases and some syndromes.

About the authors

Yu. A Bunin

Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation

Email: yabunin@outlook.com
д-р мед. наук, проф. каф. кардиологии ГБОУ ДПО РМАПО 121552, Rossiia, Moskva, ul. 3-ia Cherepkovskaia, d. 15A

References

  1. Sen-Showdhry S, Syrris P, Prasad S.K et al. Left - dominant arrhythmogenic cardiomyopathy: an under - recognized clinical entity. J Am Coll Cardiol 2008; 52: 2175-87.
  2. ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J; doi: 10.1093/eurheart/ehv316.
  3. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. Eur Heart J 2015; 36: 3227-37.
  4. Nava F, Bauce B, Basso C et al. Clinical profile and long - term follow - up of 37 families with arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2000; 36: 2226-33.
  5. Marcus F.I, Mc Kenna W.J, Shemill D. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2010; 121: 1533-41.
  6. Marcus G.M, Glidden D.V, Polonsky B et al. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2009; 54: 609-15.
  7. Moss A.J, Schuger C, Beck C.A et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 2012; 367: 2275-83.
  8. Gussak I, Brugada P, Brugada J et al. Idiopathic short QT interval: a new clinical syndrome? Cardiology 2000; 94: 99-102.
  9. Mazzanti A, Kanthan A, Monteforte N. Novel insight into the natural history of short QT syndrome. J Am Coll Cardiol 2014; 63: 1300-8.
  10. Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace 2013; 15: 1389-406.
  11. Fowler S.J, Priori S.G. Clinical spectrum of patients with Brugada ECG. Curr Opin Cardiol 2009; 24: 74-81.
  12. Fauchier L, Isorni M.A, Clementy N et al. Prognostic value of programmed ventricular stimulation in Brugada syndrome according to clinical presentation. Int J Cardiol 2013; 168: 3027-9.
  13. Priori S.G, Gasparini M, Napolitano C et al. Risk stratification in Brugada syndrome: results of the PRELUDE. J Am Coll Cardiol 2012; 59: 37-45.
  14. Priori S.G, Napolitano C, Memmi M et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002; 106: 69-74.
  15. Oechslin E, Jenni R. Left ventricular non - compaction revisited: a distinct phenotype with genetic heterogeneity? Eur Heart J 2011; 32: 1446-56.
  16. Watanаbe H, Chopra N, Liaver D et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 2009; 15: 380-3.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).